Prestige Consumer Healthcare (NYSE:PBH) Announces Earnings Results, Beats Estimates By $0.04 EPS

Prestige Consumer Healthcare (NYSE:PBHGet Free Report) announced its quarterly earnings results on Thursday. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.86 by $0.04, Briefing.com reports. The company had revenue of $267.10 million for the quarter, compared to analysts’ expectations of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.60% and a return on equity of 13.48%. Prestige Consumer Healthcare’s revenue was down 4.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.06 EPS. Prestige Consumer Healthcare updated its FY25 guidance to $4.40-4.46 EPS and its FY 2025 guidance to 4.400-4.460 EPS.

Prestige Consumer Healthcare Stock Performance

PBH traded down $0.59 during midday trading on Friday, hitting $66.25. 274,252 shares of the company traded hands, compared to its average volume of 250,556. The company has a quick ratio of 2.02, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $3.29 billion, a PE ratio of 15.89, a price-to-earnings-growth ratio of 2.00 and a beta of 0.49. The company’s 50-day moving average is $68.16 and its 200 day moving average is $68.48. Prestige Consumer Healthcare has a 52 week low of $56.34 and a 52 week high of $75.31.

Wall Street Analyst Weigh In

PBH has been the topic of a number of analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $80.00 price target on shares of Prestige Consumer Healthcare in a research note on Tuesday, May 21st. StockNews.com cut shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 21st. Finally, DA Davidson restated a “buy” rating and set a $93.00 target price on shares of Prestige Consumer Healthcare in a research note on Friday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.25.

Check Out Our Latest Research Report on Prestige Consumer Healthcare

About Prestige Consumer Healthcare

(Get Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Further Reading

Earnings History for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.